Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

IKAROS and CK2 regulate expression of BCL-XL and chemosensitivity in high-risk B-cell acute lymphoblastic leukemia
Chunhua Song, Zheng Ge, Yali Ding, et al.
Blood (2020) Vol. 136, Iss. 13, pp. 1520-1534
Open Access | Times Cited: 39

Showing 1-25 of 39 citing articles:

Strategies of Targeting CK2 in Drug Discovery: Challenges, Opportunities, and Emerging Prospects
Yijia Chen, Yuxi Wang, Jiaxing Wang, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 4, pp. 2257-2281
Closed Access | Times Cited: 40
IKZF1 Alterations and Therapeutic Targeting in B-Cell Acute Lymphoblastic Leukemia
Jonathan Paolino, Harrison Tsai, Marian H. Harris, et al.
Biomedicines (2024) Vol. 12, Iss. 1, pp. 89-89
Open Access | Times Cited: 10
Role of CK2 inhibitor CX-4945 in anti-cancer combination therapy – potential clinical relevance
Claudio D’Amore, Christian Borgo, Stefania Sarno, et al.
Cellular Oncology (2020) Vol. 43, Iss. 6, pp. 1003-1016
Open Access | Times Cited: 69
HDACs and the epigenetic plasticity of cancer cells: Target the complexity
Claudio Brancolini, Teresa Gagliano, Martina Minisini
Pharmacology & Therapeutics (2022) Vol. 238, pp. 108190-108190
Open Access | Times Cited: 31
Protein kinase CK2 – diverse roles in cancer cell biology and therapeutic promise
Janeen H. Trembley, Betsy T. Kren, Muhammad Afzal, et al.
Molecular and Cellular Biochemistry (2022) Vol. 478, Iss. 4, pp. 899-926
Open Access | Times Cited: 30
Synergistic effect of HDAC inhibitor Chidamide with Cladribine on cell cycle arrest and apoptosis by targeting HDAC2/c-Myc/RCC1 axis in acute myeloid leukemia
Siyu Gu, Yue Hou, Katarina Dovat, et al.
Experimental Hematology and Oncology (2023) Vol. 12, Iss. 1
Open Access | Times Cited: 19
CK2 and the Hallmarks of Cancer
May-Britt Firnau, Angela Brieger
Biomedicines (2022) Vol. 10, Iss. 8, pp. 1987-1987
Open Access | Times Cited: 27
The Role of Protein Kinase CK2 in Development and Disease Progression: A Critical Review
Daniel Halloran, Venu Pandit, Anja Nohe
Journal of Developmental Biology (2022) Vol. 10, Iss. 3, pp. 31-31
Open Access | Times Cited: 23
TRAF4-mediated ubiquitination-dependent activation of JNK/Bcl-xL drives radioresistance
Xin Dong, Xiaoying Li, Yu Gan, et al.
Cell Death and Disease (2023) Vol. 14, Iss. 2
Open Access | Times Cited: 11
Targeting the IKZF1/BCL-2 axis as a novel therapeutic strategy for treating acute T-cell lymphoblastic leukemia
Juan Li, Chunmei Ye, Hui Li, et al.
Cancer Biology & Therapy (2025) Vol. 26, Iss. 1
Open Access
Characterization of CK2, MYC and ERG Expression in Biological Subgroups of Children with Acute Lymphoblastic Leukemia
Luca Lo Nigro, Marta Arrabito, Nellina Andriano, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 3, pp. 1076-1076
Open Access
CK2: the master regulator in tumor immune-microenvironment - a crucial target in oncotherapy
Subhajit Karmakar, Mouli Chatterjee, Malini Basu, et al.
European Journal of Pharmacology (2025), pp. 177376-177376
Closed Access
Increased Incidence of IKZF1 deletions and IGH-CRLF2 translocations in B-ALL of Hispanic/Latino children—a novel health disparity
Gordana Raca, Hisham Abdel‐Azim, Feng Yue, et al.
Leukemia (2021) Vol. 35, Iss. 8, pp. 2399-2402
Open Access | Times Cited: 26
Cooperative Blockade of CK2 and ATM Kinases Drives Apoptosis in VHL-Deficient Renal Carcinoma Cells through ROS Overproduction
Sofia Giacosa, Catherine Pillet, Irinka Séraudie, et al.
Cancers (2021) Vol. 13, Iss. 3, pp. 576-576
Open Access | Times Cited: 23
The Immune Regulatory Role of Protein Kinase CK2 and Its Implications for Treatment of Cancer
Huixian Hong, Etty Benveniste
Biomedicines (2021) Vol. 9, Iss. 12, pp. 1932-1932
Open Access | Times Cited: 23
Selective BCL-X L Antagonists Eliminate Infected Cells from a Primary-Cell Model of HIV Latency but Not from Ex Vivo Reservoirs
Yanqin Ren, Szu-Han Huang, Amanda B. Macedo, et al.
Journal of Virology (2021) Vol. 95, Iss. 15
Open Access | Times Cited: 17
Dual targeting of MTOR as a novel therapeutic approach for high-risk B-cell acute lymphoblastic leukemia
Zheng Ge, Chunhua Song, Yali Ding, et al.
Leukemia (2021) Vol. 35, Iss. 5, pp. 1267-1278
Open Access | Times Cited: 15
Protein Kinase CK2 Regulates B Cell Development and Differentiation
Hairong Wei, Wei Yang, Huixian Hong, et al.
The Journal of Immunology (2021) Vol. 207, Iss. 3, pp. 799-808
Open Access | Times Cited: 15
Mcl‐1 and Bcl‐xL levels predict responsiveness to dual MEK/Bcl‐2 inhibition in B‐cell malignancies
Katrine Melvold, Mariaserena Giliberto, Linda Karlsen, et al.
Molecular Oncology (2021) Vol. 16, Iss. 5, pp. 1153-1170
Open Access | Times Cited: 15
Targeting the lncRNA DUXAP8/miR-29a/PIK3CA Network Restores Doxorubicin Chemosensitivity via PI3K-AKT-mTOR Signaling and Synergizes With Inotuzumab Ozogamicin in Chemotherapy-Resistant B-Cell Acute Lymphoblastic Leukemia
Li Zhang, Shixia Zhou, Tiejun Zhou, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 10
Allogeneic hematopoietic stem cell transplantation overcome the poor prognosis of patients with IKZF1plus CD20–a very high-risk subtype in B-cell acute lymphoblastic leukemia
Bingqing Tang, Zihong Cai, Zhixiang Wang, et al.
Bone Marrow Transplantation (2022) Vol. 57, Iss. 12, pp. 1751-1757
Closed Access | Times Cited: 10
Mechanistic Basis for In Vivo Therapeutic Efficacy of CK2 Inhibitor CX-4945 in Acute Myeloid Leukemia
Morgann Klink, Mohammad Atiqur Rahman, Chunhua Song, et al.
Cancers (2021) Vol. 13, Iss. 5, pp. 1127-1127
Open Access | Times Cited: 13
Inhibiting CK2 among Promising Therapeutic Strategies for Gliomas and Several Other Neoplasms
Emanuela Pucko, Robert P. Ostrowski
Pharmaceutics (2022) Vol. 14, Iss. 2, pp. 331-331
Open Access | Times Cited: 9
New precision medicine weapons for targeted treatment of high-risk B-cell precursor acute lymphoblastic leukemia
Edward A. Copelan, Robert Peter Gale
Haematologica (2024) Vol. 110, Iss. 1, pp. 4-6
Open Access | Times Cited: 1
IKZF1 in acute lymphoblastic leukemia: the rise before the fall?
Anna Østergaard, Judith M. Boer, Frank N. van Leeuwen, et al.
Leukemia & lymphoma/Leukemia and lymphoma (2024), pp. 1-11
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top